Connect with us

Media & Technology

LifeAir G1 Portable Ventilator; the Rise of Forwardly Inc.  (OTCMKTS: FORW)

Published

on

Forwardly Inc.  (OTCMKTS: FORW) is making a powerful move up the charts over the past few weeks emerging as a volume leader and exploding out of the subs and moving well into penny land. The Company is led by stock whizz George Sharp of TSNP fame who has implemented a significant share reduction slicing the authorized in half and committing itself to avoiding a reverse split of the stock.

FORW recently secured exclusive US distribution rights to LifeAir, a patent pending, non-invasive ventilator currently under development by Ligand Innovation Global, a Canadian corporation. A newer iteration of the LifeAir ventilator is currently being engineered for a summer 2020 submission to the US Food and Drug Administration (“FDA”) and Canada Health in the hopes of obtaining fast track approval. In June the Company filed its application to raise up to $15 million under Regulation A+. More recently FORW received funding commitments of $500,000 of an anticipated total of $1.3 million in financing and will itself fund Ligand Global Innovation’s development of its latest prototype of the LifeAir G1 Portable Ventilator.

Forwardly Inc.  (OTCMKTS: FORW) operating out of Boulder City, Nevada is a public company seeking opportunities to partner in fresh ideas. The company trades on the OTC Market under the symbol FORW. The company is headed by George Sharp, a former consultant to OTC Markets and a stock whizz who gets the job done right. The Company used to be Guard Dog, Inc and changed its name to Forwardly in January 2020.

LifeAir™ | Breathe Medical Devices, Inc.In June the Company filed its application to raise up to $15 million under Regulation A+. The filing includes details about Forwardly’s June 1st formation of “Breathe Medical Devices, Inc.”, a wholly owned Wyoming corporation. This subsidiary will be the operating arm for Forwardly’s recent acquisition of the exclusive US distribution rights to LifeAir, a patent pending, non-invasive ventilator currently under development by Ligand Innovation Global, a Canadian corporation.

A newer iteration of the LifeAir ventilator is currently being engineered for a summer 2020 submission to the US Food and Drug Administration (“FDA”) and Canada Health in the hopes of obtaining fast track approval. A demonstration of a prototype of the LifeAir ventilator is available for viewing at www.LigandGlobal.com. Forwardly has retained a consultant to develop its own website for the subsidiary, which is expected to be published in the next 5 to 10 days and will be located at the url “BreatheMedicalDevices.com”.

To Find out the inside Scoop on FORW Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

FORW

On August 31 FORW announced it has already received funding commitments of $500,000 of an anticipated total of $1.3 million in financing and will itself fund Ligand Global Innovation’s development of its latest prototype of the LifeAir G1 Portable Ventilator.

As announced in a June 15, 2020 press release, Forwardly, through its wholly owned subsidiary, Breathe Medical Devices, Inc., has obtained the exclusive US distribution rights to the LifeAir line of ventilator products. As part of the agreement, Forwardly also has the option to acquire up to 25% ownership interest in Ligand. Forwardly’s funding of the development of the new LifeAir G1 prototype will be applied towards the exercise of this option.

Funding for the new LifeAir G1 prototype is being raised by Forwardly through the exercise of warrants issued to purchasers of a series of debentures issued in 2019 with an aggregate total of $300,000 (the “2020 debentures”), as well as purchasers of a new series of non-toxic debentures for an aggregate total of up to $1 million. These new debentures are convertible to common stock at $.012 and set to mature in March 2022 (the “2022 debentures”).

FORW CEO George Sharp commented, “With the business world being slowed to a crawl as a result of the current pandemic, Forwardly management deemed it more expeditious to raise funds privately to enable the development of the next generation of LifeAir G1, rather than wait for the SEC’s approval of the Regulation A+ application and the subsequent time required to fund. We found our private funders to be more than eager to participate, by exercising outstanding warrants and purchasing our new series of debentures. I am proud that our private funding sources continue to support our endeavors.

https://twitter.com/Eppbankmoney/status/1332385479954755585

For more on FORW Subscribe Right Now!

FORW is making a powerful move up the charts over the past few weeks emerging as a volume leader and exploding out of the subs and moving well into penny land. The Company is led by securities whizz George Sharp of TSNP fame who has implemented a significant share reduction slicing the authorized in half and committing itself to avoiding a reverse split of the stock. FORW recently secured exclusive US distribution rights to LifeAir, a patent pending, non-invasive ventilator currently under development by Ligand Innovation Global, a Canadian corporation. A newer iteration of the LifeAir ventilator is currently being engineered for a summer 2020 submission to the US Food and Drug Administration (“FDA”) and Canada Health in the hopes of obtaining fast track approval. In June the Company filed its application to raise up to $15 million under Regulation A+. More recently FORW received funding commitments of $500,000 of an anticipated total of $1.3 million in financing and will itself fund Ligand Global Innovation’s development of its latest prototype of the LifeAir G1 Portable Ventilator. We will be updating on FORW when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with FORW.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in FORW either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.